Document is current

Article History

Received: 23 December 2025

Revised: 12 March 2026

Accepted: 25 March 2026

First Online: 9 April 2026

Declarations

:

: VZ: none; TR: none; YM: lecture honoraria from Alfasigma, Lilly, and Pfizer; DB: payment/honoraria from AbbVie, Alfasigma, Lilly, Novartis, UCB, and Celltrion; PH: payment/honoraria from Novartis, AbbVie, Janssen, and Celltrion. UK: Dr. Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biocad, Biogen, Chugai, Eli Lilly, Fresenius, Gilead, Grünenthal, GSK, Janssen, MSD, Novartis, Pfizer, Roche, and UCB. CK: consulting fees from AstraZeneca, Galapagos, and MICE Service GmbH and payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from AbbVie, AstraZeneca, Boehringer-Ingelheim, Celltrion, GSK, Pfizer, and UCB. AS: lecture honoraria from AbbVie, Amgen, BMS, Celltrion, MSD, Lilly, Pfizer, Roche, and UCB.

: The study protocol was approved by the ethics committee of the Charité University Medicine Berlin.

: Obtained.

: Results were presented and discussed in the presence of patient research partners of the TARISMA (Targeted Risk Management in Musculoskeletal Diseases) research network.